Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis

Despite the same manufacturer, the same drotrecogin alfa activated dose, and the same placebo-controlled design, the negative result from the PROWESS-SHOCK trial contradicted the survival benefit observed in the PROWESS trial. We hypothesize that the different results were due to factors other than...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalil, Andre C, Florescu, Diana F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706817/
https://www.ncbi.nlm.nih.gov/pubmed/23826709
http://dx.doi.org/10.1186/cc12752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706817/
https://www.ncbi.nlm.nih.gov/pubmed/23826709
http://dx.doi.org/10.1186/cc12752

Ejemplares similares